Video

Dr. Nancy Lewis Discusses the Regorafenib CORRECT Trial

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Nancy L. Lewis, MD, Clinical Director, Experimental Therapeutics, Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib (Stivarga).

The CORRECT trial enrolled 760 patients with heavily pretreated metastatic colorectal cancer (mCRC) who had exhausted all approved treatment options, including chemotherapy, bevacizumab (Avastin), cetuximab (Erbitux), and panitumumab (Vectibix). Patients were randomized 2:1 to receive regorafenib or placebo plus best supportive care for 21 days with 1 week off.

At the 2012 ESMO congress, the final analysis from the CORRECT trial for overall survival (OS) was presented and further confirmed the benefits of regorafenib. At the final analysis, median OS was 6.4 months for regorafenib compared to 5 months for placebo.

The FDA approved regorafenib on September 27, 2012, as a salvage therapy for patients with mCRC. Lewis believes the approval of regorafenib will play a major roll in allowing patients with mCRC to live longer.

<<<

View more from the 2012 ESMO Congress

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine